SMAD3 and asthma: Nine of the 40 prioritized genes are the targets of existing asthma drugs including IL4R (dupilumab), SMAD3 (corticosteroids), IL6 (clazakizumab, sirukumab), TNFSF4 (oxelumab), TSLP (tezepelumab), CCR4 (mogamulizumab), IL13 (anrukinzumab, lebrikizumab, dectrekumab, tralokinumab), IL5 (mepolizumab, reslizumab), and IL2RA (daclizumab).